Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30665869

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2019 Feb
First author
Zhu AX

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Feb;20(2):177-179. doi: 10.1016/S1470-2045(19)30009-9.
    note
    Source null
    related pmid
    30665868
    relationship
    Comment in
  2. citation
    Hepatobiliary Surg Nutr. 2019 Oct;8(5):515-518. doi: 10.21037/hbsn.2019.04.19.
    note
    Source null
    related pmid
    31673543
    relationship
    Comment in
  3. citation
    Hepatobiliary Surg Nutr. 2019 Oct;8(5):546-548. doi: 10.21037/hbsn.2019.04.14.
    note
    Source null
    related pmid
    31673554
    relationship
    Comment in
  4. citation
    Chin Clin Oncol. 2020 Aug;9(4):58. doi: 10.21037/cco.2020.01.04.
    note
    Source null
    related pmid
    32156118
    relationship
    Comment in

Authors and identifiers

  1. name
    Zhu AX
    type
    Author
  2. name
    Kang YK
    type
    Author
  3. name
    Yen CJ
    type
    Author
  4. name
    Finn RS
    type
    Author
  5. name
    Galle PR
    type
    Author
  6. name
    Llovet JM
    type
    Author
  7. name
    Assenat E
    type
    Author
  8. name
    Brandi G
    type
    Author
  9. name
    Pracht M
    type
    Author
  10. name
    Lim HY
    type
    Author
  11. name
    Rau KM
    type
    Author
  12. name
    Motomura K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zhu AX
    type
    Author
  2. name
    Kang YK
    type
    Author
  3. name
    Yen CJ
    type
    Author
  4. name
    Finn RS
    type
    Author
  5. name
    Galle PR
    type
    Author
  6. name
    Llovet JM
    type
    Author
  7. name
    Assenat E
    type
    Author
  8. name
    Brandi G
    type
    Author
  9. name
    Pracht M
    type
    Author
  10. name
    Lim HY
    type
    Author
  11. name
    Rau KM
    type
    Author
  12. name
    Motomura K
    type
    Author
bibliography ids
  1. nci-bib-d30d40d75c1a6370ca9bbb2a
book metadata
content sha256
ca4fe25dd7125dbcc3618bc36a5a731e43cf7abe20ae34dbb3372bc8cb334382
document type
citation
dois
  1. 10.1016/S1470-2045(18)30937-9
electronic publication date
display
2019 Jan 18
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:30665869
immutable id
pubmed:30665869@ca4fe25dd7125dbcc3618bc36a5a731e43cf7abe20ae34dbb3372bc8cb334382
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
282-296
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Feb;20(2):177-179. doi: 10.1016/S1470-2045(19)30009-9.
    note
    Source null
    related pmid
    30665868
    relationship
    Comment in
  2. citation
    Hepatobiliary Surg Nutr. 2019 Oct;8(5):515-518. doi: 10.21037/hbsn.2019.04.19.
    note
    Source null
    related pmid
    31673543
    relationship
    Comment in
  3. citation
    Hepatobiliary Surg Nutr. 2019 Oct;8(5):546-548. doi: 10.21037/hbsn.2019.04.14.
    note
    Source null
    related pmid
    31673554
    relationship
    Comment in
  4. citation
    Chin Clin Oncol. 2020 Aug;9(4):58. doi: 10.21037/cco.2020.01.04.
    note
    Source null
    related pmid
    32156118
    relationship
    Comment in
outcomes validated
false
pmid
30665869
provenance
batch id
e808962322f3afebc564
provider
NCBI PubMed ESummary
record sha256
dcdea91f7e60b6eab4d819cb2352f69297480b28ae387f4532b24f2c3d743363
response sha256
3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
retrieved at
2026-09-09T23:47:41.002093+00:00
publication date
display
2019 Feb
precision
month
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30665869/
title
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice